Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents

Journal of Medicinal Chemistry

Volumn 39, Issue 7, 1996, Pages 1509-1513

  Flaherty, Patrick T ^a   Greenwood, Thomas D ^a   Manheim, Amy L ^a   Wolfe, James F ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; ETHOSUXIMIDE; FLUNITRAZEPAM; N (PHENYLACETYL)TRIFLUOROMETHANESULFONAMIDE; PHENOBARBITAL; PHENYTOIN; PICROTOXIN; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CALCULATION; CONVULSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SCREENING; GABAERGIC TRANSMISSION; LETHAL DOSE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; QUANTITATIVE DIAGNOSIS; RECEPTOR BINDING; SEIZURE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICONVULSANTS; BODY WEIGHT; CYTOCHROME P-450 ENZYME SYSTEM; EPILEPSY; MESYLATES; MICE; NADPH-FERRIHEMOPROTEIN REDUCTASE; ORGAN SIZE; OXIDOREDUCTASES, O-DEMETHYLATING; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0029886374     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950761q     Document Type: Article

References (36)

1. Shorvon, S. D. Epidemiology, Classification, Natural History and Genetics of Epilepsy. Lancet 1990, 336, 93-96.
2. Brodie, M. J. Established Anticonvulsants and Treatment of Refractory Epilepsy. Lancet 1990, 338, 350-354.
3. Meldrum, B. S., Porter, R. J., Eds. In New Anticonvulsant Drugs. Current Problems in Epilepsy 4; John Libbey: London, 1986.
4. Leppik, I. E. Antiepileptic Drugs in Development: Prospects for the Near Future. Epilepsia 1994, 35 (Suppl. 4), S29-S40.
5. (a) Gray, W. D., Maren, T. H.; Sisson, B. M.; Smith, F. H. Carbonic Anhydrase Inhibition VII. Carbonic Anhydrase Inhibition and Anticonvulsant Effect. J. Pharmacol. Exp. Ther. 1957, 121, 160-170.
6. (b) Holland, G. F.; Funderburk, W. H.; Finger, K. F. Preparation and Anticonvulsant Activity of N-Substituted Benzenedisulfonamides. J. Med. Chem. 1963, 6, 307-312.
7. (c) Tanimukai, H.; Inui, M.; Hariguchi, S.; Kaneko, Z. Antiepileptic Property of Inhibitors of Carbonic Anhydrase. Biochem. Pharmacol. 1965, 14, 961-970.
8. (d) Hamor, G. H.; Reavlin, B. L. Anticonvulsants III. Alkyl Esters of 4-Bromo-2-sulfamoylbenzoic Acid. J. Pharm. Sci. 1967, 56, 134-136.
9. (e) Lukes, J. J.; Nieforth, K. A. Substituted Thiadiazolines as Inhibitors of Central Nervous System Carbonic Anhydrase. J. Med. Chem. 1975, 18, 351-354.
10. Oles, K. S.; Penry, J. K.; Cole, D. L. W.; Howard, G. Use of Acetazolamide as an Adjunct to Carbamazepine in Refractory Partial Seizures. Epilepsia 1989, 30 (1), 74-78.
11. (a) Uno, H.; Kurokawa, M.; Masuda, Y.; Nishimura, H. Studies on 3-Substituted 1,2-Benzisoxazole Derivatives 6. Syntheses of 3-(Sulfamoylmethyl)-1,2-benzisoxazole Derivatives and Their Anticonvulsant Activities. J. Med. Chem. 1979, 22, 180-183.
12. (b) Masuda, Y.; Karasawa, T.; Shiraishi, Y.; Hori, M.; Yoshida, K.; Shimizu, M. 3-Sulfamoylmethyl-1,2-benzisoxazole, a New Type of Anticonvulsant Drug. Arzneim.-Forsch. / Drug Res. 1980, 30 (I), 477-483.
13. Moore, G. I.; Conway, A. C. N,N-Disubstituted Trifluoromethane-sulfonamides. U.S. Patent 3,609,187, 1971; Chem. Abstr. 1971, 75, P151529d.
14. Moore, G. I.; Conway, A. C. N,N-Disubstituted Trifluoromethane-sulfonamides. U.S. Patent 3,609,187, 1971; Chem. Abstr. 1971, 75, P151529d.
15. Moore, G. I. N-Acylated Perfluroralkanesulfonamides. U.S. Patent 3,622,626, 1971; Chem. Abstr. 1971, 76, P45941t.
16. Moore, G. I. N-Acylated Perfluroralkanesulfonamides. U.S. Patent 3,622,626, 1971; Chem. Abstr. 1971, 76, P45941t.
17. Moore, G. I.; Conway, A. C. Fluoroalkanesulfonamides. U.S. Patent 3,637,840, 1972; Chem. Abstr. 1972, 76, P71557c.
18. Moore, G. I.; Conway, A. C. Fluoroalkanesulfonamides. U.S. Patent 3,637,840, 1972; Chem. Abstr. 1972, 76, P71557c.
19. Goehring, R. R.; Greenwood, T. D.; Nwokogu, G. C.; Pisipati, J. S.; Rogers, T. G.; Wolfe, J. F. Synthesis and Anticonvulsant Activity of 2-Benzylglutarimides. J. Med. Chem. 1990, 33, 926-931.
20. Goehring, R. R.; Greenwood, T. D.; Pisipati, J. S.; Wolfe, J. F. Synthesis and Anticonvulsant Evaluation of Some New 2-Benzylsuccinimides. J. Pharm. Sci. 1991, 80, 790-792.
21. Topliss, J. G. Utilization of Operational Schemes for Analog Synthesis in Drug Design. J. Med. Chem. 1972, 15, 1006-1011.
22. (a) Anticonvulsant Screening Project, Antiepileptic Drug Development Program; National Institutes of Health, DHEW Publ (NIH) (US), 1978; pp 78-1093.
23. (b) Krall, R. L.; Penry, J. K.; White, B. G.; Kupferberg, H. J.; Swinyard, E. A. Antiepileptic Drug Development: II. Anticonvulsant Drug Screening. Epilepsia 1978, 19, 409-428.
24. (c) Porter, R. J.; Cereghino, J. J.; Gladding, G. D.; Hessie, B. J.; Kupferberg, H. J.; Scotville, B.; White, B. G. Antiepileptic Drug Development Program. Cleveland Clin. Q. 1984, 51, 293-305.
25. (d) Swinyard, E. A.; Wolf, H. H.; Franklin, M. R.; Chweh, A. Y.; Woodhead, J. H.; Kupferberg, H. J.; Gladding, G. D. The Early Evaluation of Anticonvulsant Drugs; Technical Report for 79146 on Contract No. N01-N5-4-2361; Epilepsy Branch, National Institute of Neurological and Communicative Disorders and Stroke: Bethesda, MD, 1984.
26. Greater efficacy against MES-induced seizures than against scMet-induced convulsions appears to be a phenomenon common to many anticonvulsant primary sulfonamides, see refs 5-7.
27. This lack of activity against scMet seizures was verified by ip administration of doses of 25, 50, and 100 mg/kg of 3a to three groups of two rats each. This resulted in neurotoxicity in all animals and no protection by the scMet test.
28. These results are similar to those reported for zomsamide after 7-day tolerance studies (see ref 7b) but contrast with the rapid development of tolerance observed with acetazolamide, see ref 6.
29. Development of tolerance is indicated by a shorter sleep time in chronically treated animals, see ref 14c.
30. Flat regression lines are indicative of a wide dosage range between zero and 100% anticonvulsant effect of the test drug.
31. Enna, S. J.; Snyder, S. H. Influences: Ions, Enzymes, and Detergents on Gamma-aminobutyric Acid Receptor Binding in Synaptic Membranes of Rat Brain. Mol. Pharmacol. 1977, 13, 442-453.
32. Ticku, M. K.; Burch, T. Alterations in Gamma-aminobutyric Acid Receptor Sensitivity Following Acute and Chronic Ethanol Treatment. J. Neurochem. 1980, 34, 417-423.
33. 3H) Diazepam Binding. Proc. Nat. Acad. Sci. U.S.A. 1977, 74, 3805-3809.
34. Zukin, S. R.; Young, A. B.; Snyder, S. H. Gamma-aminobutyric Acid Binding to Receptor Sites in the Rat Central Nervous System. Proc. Nat. Acad. Sci. U.S.A. 1974, 71, 4802-4807.
35. Enna, S. J.; Snyder, S. H. Properties of Gamma-aminobutryic Acid (GABA) Receptor Binding in Rat Brain Synaptic Membrane Fractions. Brain Res. 1975, 100, 81-97.
36. Franklin, M. R.; Estabrook, R. W. On the Inhibitory Action of Mersalyl on Microsomal Drug Oxidation: a Rigid Organization of the Electron Transport Chain. Arch. Biochem 1971, 143, 318-329.